CD200R1 and neoplasm: Based on analogous studies with other checkpoint inhibitors that have shown a relationship between tumor pathway expression [e.g., PD-(L)1] and clinical response to pembrolizumab (23), nivolumab (24), and atezolizumab (25), baseline assessments for tumor CD200R1 and CD200 expressions were performed to evaluate potential correlates with efficacy.